Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide

Inclusion Criteria

Ability and willingness of participant or legal guardian/representative to provide informed consent.

HIV-1, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, or plasma HIV-1 RNA viral load. If a rapid HIV test or any FDA-approved HIV-1 E/CIA test kit is not available, two HIV-1 RNA values ≥2000 copies/mL at least 24 hours apart may be performed by any US laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent, or by any non-US laboratory that is DAIDS Good Clinical Laboratory Practice (GCLP) compliant and, if performing HIV-1 RNA testing, is Virology Quality Assurance (VQA)-certified.

Currently on a bictegravir (BIC), dolutegravir (DTG), or raltegravir (RAL) + TAF/FTC regimen with ≥48 weeks prior to study entry.

Ability to acquire NRTIs (TAF/FTC or TDF/FTC) and INSTI through usual care for the duration of the study.

A BMI ≥30 kg/m2 at screening. No known plans to change or to initiate medications known to be associated with significant weight changes during study period.

Agree to adhere to assigned ART during the study period At least one HIV-1 RNA level 50) performed in the 48 weeks prior (≤48 weeks) to study screening, and at least one HIV-1 RNA level 50) performed within 45 days prior to study entry by any US laboratory that possesses a CLIA certification or its equivalent, or at any network-approved non-US laboratory that is VQA certified.

For participants capable of becoming pregnant, negative serum or urine pregnancy test within 45 days prior to study entry by any US clinic or laboratory that has a CLIA certification or its equivalent, or is using a point of care (POC)/ CLIA-waived test, or at any network-approved non-US laboratory or clinic that operates in accordance with GCLP and participates in appropriate external quality assurance programs.

Participants engaging in sexual activity and capable of becoming pregnant must agree to use contraception while on study drug (approximately 48 weeks) and for 8 weeks after the end of the study. At least one of the following contraceptive methods must be used:

• Intrauterine device (IUD)
• Hormone-based contraceptive
• Partner sterilization (i.e., vasectomy) and is the sole partner for the participant.

Transgender participants who are currently taking hormones must be on a stable hormone dose for >12 weeks prior to study entry. Transgender participants should not have active plans to change their hormone regimen or dose during the study period.

The following laboratory values obtained within 45 days prior to study entry by any US laboratory that has a CLIA certification or its equivalent, or at any network-approved non-US laboratory that operates in accordance with GCLP and participates in appropriate external quality assurance programs:

• Absolute neutrophil count (ANC) >750 cells/mm3
• Hemoglobin >10 g/dL for males and >9 g/dL for females (based on sex at birth)
• Calculated creatinine clearance ≥50 mL/min as estimated by the CKD-EPI equation (a calculator is available at: https://qxmd.com/calculate/calculator\_251/egfr-using-ckd-epi)
• Aspartate aminotransferase (AST) (SGOT) 1000 copies/mL after having achieved viral suppression.

Prior exposure to single-dose nevirapine for the prevention of parent-to-child transmission of HIV.

Any history of significant renal toxicity while taking TDF (as determined by the site investigator).

Currently breast-feeding or pregnant, or intending to become pregnant during the duration of the study.

Current use, use in the 4 weeks preceding study entry, or anticipated use of prohibited drugs during the study period.

Anticipated start or cessation of any of the following drugs during the study period:

• Antipsychotics (e.g., clozap